Quantisnow Logo
Dashboard

IQVIA named to the Fortune® World's Most Admired Companies™ list, ranked No. 1 in its sector for fourth consecutive year

$IQV
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Get the next $IQV alert in real time by email

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World's Most Admired Companies™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on four key attributes — innovation, global competitiveness, people management and use of corporate assets.

"We are deeply honored to be recognized for the fourth year in a row as number one on the World's Most Admired Companies list for our category, and to be named to the list for the eighth consecutive year," said IQVIA Chairman and CEO Ari Bousbib. "This distinction reflects the dedication and impact our employees have in advancing our mission to accelerate innovation for a healthier world. Their commitment and deep expertise drive innovative medical treatments that enhance patient outcomes globally."

The Fortune® World's Most Admired Companies™ list is the definitive report card on corporate reputations. Since 1997, Fortune® has identified, selected and ranked the World's Most Admired Companies™, identifying the business practices that make these companies highly regarded among their peers.

Most Admired Company survey methodology

The annual survey, conducted by Fortune® and Korn Ferry, a global organizational consulting firm, is given to top executives, directors and financial analysts, to identify the companies that enjoy the strongest reputations within their industries and across industries.

Fortune® and Korn Ferry analyzed 650 companies and surveyed more than 3,300 executives to measure reputation based on nine different attributes, including each firm's effectiveness in conducting business globally, its ability to attract, develop, and keep talent, its value as a long-term investment, its innovativeness, its wise use of corporate assets, and its responsibility to the community and environment.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, ensuring that its AI-powered capabilities are grounded in privacy, regulatory compliance, and patient safety. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

 Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)

+1.973.541.3558

Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)

+1.919.923.6785

Get the next $IQV alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IQV

DatePrice TargetRatingAnalyst
4/10/2025$170.00Overweight → Equal Weight
Barclays
2/3/2025Buy → Neutral
BTIG Research
12/20/2024$250.00Overweight
Stephens
10/14/2024Buy
Redburn Atlantic
9/4/2024$275.00Outperform
RBC Capital Mkts
7/24/2024$266.00 → $242.00Buy → Hold
Jefferies
6/6/2024$270.00Buy
Goldman
2/26/2024$290.00Outperform
Leerink Partners
More analyst ratings

$IQV
 Press Releases

Fastest customizable press release news feed in the world

See more

  • IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm

    IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced today that the global independent research and analysis firm Everest Group® has named IQVIA a "front-runner generative AI leader" for the life sciences industry in its recent report, "AI-deas to Action: Operationalizing Generative AI in Life Sciences." IQVIA was the only clinical research organization to receive the highest ranking of front-runner in the report, which measures the value impact of end-to-end generative AI capabilities for 15 carefully selected broad-based AI companies, CROs and life sciences specialists and niche firms. IQVIA is also the only

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

  • IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

  • Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report

    Research and development funding has increased: Biopharma funding increased for the second consecutive year in 2024. Total large-pharma R&D spending continued to increase. Clinical trial start volumes have stabilized: Trial starts have fully returned to pre-pandemic levels. Priorities have continued to shift. Clinical program productivity has increased: Improvement in productivity was driven by a success-rate increase in Phase III trials. Cycle times are stabilizing: Enrollment duration – the largest opportunity to improve trial cycle times – stabilized in 2024 after having increased between 2021 and 2023. Inter-trial intervals now typically account for 17 months

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$IQV
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$IQV
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$IQV
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$IQV
 SEC Filings

See more

$IQV
 Leadership Updates

Live Leadership Updates

See more

  • IQVIA Appoints Richard Staub III President of Research & Development Solutions

    IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

  • IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

    IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

  • IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$IQV
 Financials

Live finance-specific insights

See more

  • IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

  • IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance

    Revenue of $3,958 million for the fourth quarter, $15,405 million for the full year GAAP Net Income of $437 million for the fourth quarter, $1,373 million for the full year Adjusted EBITDA of $996 million for the fourth quarter, $3,684 million for the full year GAAP Diluted Earnings per Share of $2.42 for the fourth quarter, $7.49 for the full year Adjusted Diluted Earnings per Share of $3.12 for the fourth quarter, $11.13 for the full year R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x R&D Solutions contracted backlog of $31.1 billion, up 5.5 percent year-over-year at constant currency TAS Revenue of $1,658 million fo

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

  • IQVIA to Announce Fourth-Quarter and Full-Year 2024 Results on February 6, 2025

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, part

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$IQV
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more